Mechanism of Action.
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Its 39-amino-acid structure is based on the GIP sequence with modifications that enable GLP-1 receptor binding. A C-20 fatty di-acid moiety enables albumin binding for extended half-life. The dual mechanism provides complementary metabolic effects: GLP-1 receptor activation drives appetite suppression, delayed gastric emptying, and glucose-dependent insulin secretion, while GIP receptor activation enhances insulin sensitivity, may improve lipid metabolism in adipose tissue, and potentially contributes additional central appetite regulation. The combined signaling appears to produce greater metabolic effects than GLP-1 agonism alone.
Research Summary.
Tirzepatide has produced the most impressive weight loss data of any pharmaceutical intervention studied in randomized controlled trials. The SURMOUNT-1 trial demonstrated 22.5% mean weight loss at the 15mg dose over 72 weeks in participants with obesity. In the SURPASS program for type 2 diabetes, tirzepatide showed superior A1C reduction compared to semaglutide 1mg (SURPASS-2). The SURMOUNT-2 trial in patients with obesity and T2DM showed 14.7% weight loss at 15mg. Research into tirzepatide for MASH, heart failure with preserved ejection fraction (HFpEF), and obstructive sleep apnea has shown positive results. The SUMMIT trial demonstrated improved heart failure outcomes in HFpEF patients.
Side Effects & Safety.
The side effect profile is similar to GLP-1 agonists, with gastrointestinal events being most common. In SURMOUNT-1, nausea occurred in 31% (15mg dose), diarrhea in 23%, constipation in 11%, and vomiting in 13%. GI events are typically transient and most prevalent during dose escalation. Serious adverse events include rare pancreatitis, gallbladder events, and the same thyroid C-cell boxed warning as semaglutide. Hypoglycemia risk is low when used without sulfonylureas or insulin. As with semaglutide, concurrent lean mass loss requires attention to resistance training and protein intake.
Legal Status & Access.
Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes (5mg, 10mg, 15mg weekly injection) and as Zepbound for chronic weight management (same doses). It is prescription-only. Research-grade tirzepatide is available from peptide and GLP-1 research suppliers for laboratory investigation.